Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05208086 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

Study acronym: RHUMM
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 13, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Study sites: 20 to 18 · Completion date: May 2027 to May 2026 · Study description revisedv5 Show 3 more changesShow less
    • Study sites: 20 to 18
    • Completion date: May 2027 to May 2026
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  2. Enrollment target: 300 to 180 Primary completion date: Jun 2025 to May 2026 · Study sites: 22 to 20 · Completion date: Jun 2026 to May 2027 · 1 morev4 Show 4 more changesShow less
    • Primary completion date: Jun 2025 to May 2026
    • Study sites: 22 to 20
    • Completion date: Jun 2026 to May 2027
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jul 2024 to Jun 2025 Study sites: 20 to 22 · Completion date: Jul 2025 to Jun 2026v3 Show 2 more changesShow less
    • Study sites: 20 to 22
    • Completion date: Jul 2025 to Jun 2026
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 20 · Start date changed from estimate of Feb 2022 to May 18, 2022v2 Show 2 more changesShow less
    • Study sites: 0 to 20
    • Start date changed from estimate of Feb 2022 to May 18, 2022
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.
Trial Details
NCT Number NCT05208086
Lead Sponsor Intergroupe Francophone du Myelome
Conditions Multiple Myeloma
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov